- Nano Express
- Open Access
The Effect of Iron Oxide Magnetic Nanoparticles on Smooth Muscle Cells
© to the authors 2008
- Received: 17 September 2008
- Accepted: 29 October 2008
- Published: 2 December 2008
Recently, magnetic nanoparticles of iron oxide (Fe3O4, γ-Fe2O3) have shown an increasing number of applications in the field of biomedicine, but some questions have been raised about the potential impact of these nanoparticles on the environment and human health. In this work, the three types of magnetic nanoparticles (DMSA-Fe2O3, APTS-Fe2O3, and GLU-Fe2O3) with the same crystal structure, magnetic properties, and size distribution was designed, prepared, and characterized by transmission electronic microscopy, powder X-ray diffraction, zeta potential analyzer, vibrating sample magnetometer, and Fourier transform Infrared spectroscopy. Then, we have investigated the effect of the three types of magnetic nanoparticles (DMSA-Fe2O3, APTS-Fe2O3, and GLU-Fe2O3) on smooth muscle cells (SMCs). Cellular uptake of nanoparticles by SMC displays the dose, the incubation time and surface property dependent patterns. Through the thin section TEM images, we observe that DMSA-Fe2O3is incorporated into the lysosome of SMCs. The magnetic nanoparticles have no inflammation impact, but decrease the viability of SMCs. The other questions about metabolism and other impacts will be the next subject of further studies.
- Magnetic nanoparticles
- Iron oxide
- Smooth muscle cells
- Cellular uptake
Magnetic nanomaterial has shown an increasing number of applications in different fields of information, mechanics, and biomedicine due to their multifunctional properties such as small size effect, superparamagnetism, inherently biocompatibility, etc. [1–4]. Especially in the last decade, the field of biomedicine witnessed an explosion of interest in the use of magnetic nanomaterial in earlier diagnosis and effective treatment of some diseases, such as magnetic resonance imaging (MRI) [5, 6], drug delivery [7–11], hyperthermia, etc. [12, 13]. In MRI, magnetic nanoparticles serve as contrast enhancement agents, in drug delivery, they function as drug carriers delivering and releasing the drug into target cells, while in hyperthermia, they serve as generator of heat under alternating current magnetic field. In certain cases, the employment based on magnetic nanomaterial has displayed significant advantages over conventional material with regard to assay sensitivity, effect of treatment, side effect, etc.
In biological applications, the current magnetic nanoparticles (MNPs) of iron oxide (Fe3O4, γ-Fe2O3) may be modest and biocompatible [14, 15], but some questions have been raised about the potential impact of these nanoparticles on the environment and human health. Numerous investigations have been carried out using iron oxides nanoparticles linked to their high mobility and specific reactivity with cells. Some results indicate that iron oxide nanoparticles could be internalized by cells and induce a dramatic decrease in the metabolic activity and proliferation of human cells (MSTO-211H) [16–20]. A quantifiable model cell system shows that intracellular delivery of even moderate levels of iron oxide (Fe2O3) nanoparticles may adversely affect cell function. More specifically, the cytotoxicity studies show that exposure to increasing concentrations of anionic MNPs, from 0.15 to 15 mM of iron, results in a dose-dependent diminishing viability and capacity of PC12 cells to extend neurites in response to nerve growth factor .
Recently, the cytotoxicity assessment about iron oxide nanoparticles has been focused on by more and more researchers. Nevertheless, as mentioned by Auffan et al. , toxicological data are difficult to compare since the parameters controlled in each of these studies may differ. These parameters involve size distribution, surface properties, magnetic properties, stability in biological media, etc. In this present study, the aim is to elucidate the effect of different iron oxide magnetic nanoparticles (γ-Fe2O3, MNPs) on Sprague-Dawley rat smooth muscle cell (SMC) in vitro. In particularly, MNPs were coated by meso-2, 3-dimercaptosuccinic acid (DMSA), 3-amino-propyltriethoxysilane (APTS), and l-glutamic acid (GLU), respectively, but possess the same size distribution and magnetic properties and stability, which can ensure the consistence and comparability of investigation results.
Magnetic nanoparticles were synthesized, and stored in the dark at 4 °C. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from GIBCO Company. Penicillin and streptomycin were purchased SIGMA Company. TNF-α ELISA Kit was purchased from BOSTER Company. All of other chemicals were of reagent grade and were used as received without further purification. Double distilled water was used for all the experiments.
Preparation of the Coated MNPs
Fe3O4 nanoparticles were synthesized by chemical coprecipitation of Molday . Typically, a solution of mixture of FeCl3 and FeSO4 (molar ratio 2:1) was prepared under N2 protecting, followed by the slow addition of enough ammonia aqueous solution with vigorous stirring for 30 min. The black Fe3O4 precipitates were obtained and washed immediately with distilled water for five times by magnetic separation. The final precipitates were dispersed in distilled water with concentration of 0.128 M and pH 3.0, and oxidized into more stable MNPs (γ-Fe2O3) by air at the temperature of 90 °C.
According to the process described in the literature [23, 24], MNPs were coated with DMSA and GLU. Finally stable aqueous sol DMSA-MNPs (DMSA-Fe2O3), and GLU-MNPs (GLU-Fe2O3) were obtained. Similarly, APTS-MNPs (APTS-Fe2O3) were prepared according to literature . The part of above samples was dried into powder at room temperature under vacuum.
The particle size and morphology of the coated MNPs was determined by transmission electronic microscopy (TEM, JEOL, JEM-200EX). Powder X-ray diffraction (XRD, Rigaku, D/Max-RA, λ = 1.5405 × 10−10 m, CuK) was used to determine the crystal structure of MNPs. Surface charge measurements were performed with a zeta potential analyzer (BECKMAN, Delsa 440SX). The magnetic measurements were carried out with a vibrating sample magnetometer (VSM, Lakeshore 7407). Fourier transform infrared (FTIR) spectroscopy measurements were performed on a Bruker Fourier transform spectrometer model VECTOR22 using KBr pressed discs.
Sprague-Dawley (SD) rat aortic SMCs were grown from explants of normal SD rat aorta fragments. Cells were further cultured in Dulbecco’s modified Eagle medium (DMEM) containing 15% fetal bovine serum (FBS), penicillin (100 μg/mL), and streptomycin (100 μg/mL), in 5% CO2chamber.
Incubation of SMC with the Coated MNPs
All the coated MNPs was sterilized with filter-film (pore size, 0.22 μm) and sonicated before dilution into DMEM culture medium to ensure even particle suspension. Then, the MNPs were diluted with DMEM at different concentration and added into the plates in triplicate for a further specified time after the normal medium was removed. All control cells were cultured in the absence of any particles. Every experiment was repeated at least three times independently.
Cellular Uptake of MNPs Assay
Cellular uptake of MNPs was evaluated according to the method of Petri-Fink . The supernate of cells on the 6-well plates was removed and cells were thoroughly washed with PBS and resuspended in 2 M HCl (1 mL/well of a 6-well plate) at 37 °C for 2 h. The protein concentration of mixture was determined at 280 nm by Ultraviolet Visible Spectrophotometer (UV–vis). 1 mL of 5% solution of K4[Fe(CN)6 in H2O was added, and the absorbance of samples was read after 10 min at 690 nm. A standard curve of an aqueous FeCl3 · 6H2O solution was treated in the same conditions to quantify the amount of cellular uptake of MNPs. The cellular uptake of MNPs was expressed at the amount of Fe2O3 (weight, μg) per milligram of protein.
The SMC incubated with DMSA-MNPs for 24 h were washed with PBS and fixed in 4% glutaraldehyde solution for 1 h at 4 °C. The cells were postfixed in 1% osmium tetroxide for 1 h at room temperature and washed. Then, cells were scraped and concentrated in 2.5% agar in 0.05 M cacodylate buffer. The obtained samples were then treated with 2% uranyl acetate solution for 1 h and subsequently dehydrated by means of ethanol/water solutions, with increasing ethanol content and embedded in epoxy resin . The samples were cut at 70 nm (ultrathin sections) with an ultramicrotome. Ultrathin sections were transferred to the 300 mesh copper grid and stained with 5% uranyl acetate. The copper grid was observed on a transmission electron microscope (TEM, HITACHIH-600) at 80 kV.
After incubation for a period of time, cell culture supernate was collected and centrifuged at 8,000×g for 30 min to remove cell debris and nanoparticles. Tumor necrosis factor α (TNF-α) protein concentrations in the supernate were measured using an ELISA kit (RAT TNF-α, ELISA KIT, BOSTER) according to the manufacturer’s instructions.
Cell Viability Assay
Viability of SMC was determined by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide) assay. After incubation the supernate was removed and 200 μL MTT solution (0.5 mg/mL in DMEM medium) was added at 37 °C for 2 h. Then, cells were rinsed two times with PBS and 150 μL extracting solution (0.04 M HCl in isopropanol) was added to each well of 96-well plates. The plates were placed for 15 min at ambient temperature to dissolve the dyes and the dye extract was transferred to 96 well Elisa plates. Absorbance was assayed at 570 nm by Ultra Microplate Reader ELX808 IU (Bio-Tek) and the cell viability was expressed in percent based on the control.
Preparation of the Coated MNPs and Characterization
Cellular Uptake of MNPs
The cellular uptake indicates a function of surface properties of MNPs. From Fig. 6c, there is obvious difference among the three types of MNPs at the same concentration (0.1 mg/mL) for the same incubation time (24 h). The uptake amount of APTS-MNPs, GLU-MNPs, and DMSA-MNPs are 3.72, 4.60, and 8.98 μg per milligram protein, respectively. We infer that the different surface properties, such as charges of surface molecules, result in the different affinity with SMC [27, 29–32]. According to the results, it is promising to facilitate or alter uptake of SMC by altering the surface properties of MNPs.
Endocytosis of DMSA-MNPs by SMC
SMC Viability/Cytotoxicity Studies
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide) assay is a simple nonradioactive colorimetric assay to measure cell cytotoxicity, proliferation, or viability . The active SMC is able to convert this dye into a water-insoluble dark-blue formazan by reductive cleavage of the tetrazolium ring . Formazan crystals, then, was dissolved in acidification isopropanol by measuring the absorbance of the solution at 570 nm, and the resultant value is related to the number of living cells.
However, the viability of SMC has not shown obviously statistical difference when incubated with three types of MNPs at the same concentration (0.1 mg/mL) and incubation time (24 h), which demonstrates that the properties of MNPs (used in the experiments) hardly have effect on the viability of SMC. The data are shown in Fig. 9c.
The work has focused on the effect of iron oxide magnetic nanoparticles on SMCs. The magnetic nanoparticles (DMSA-MNPs APTS-MNPs, and GLU-MNPs) have the same crystal structure, magnetic properties, and size distribution. Cellular uptake of MNPs displays the dose, the incubation time, and surface property dependent patterns. Through the thin section TEM images, we observe that DMSA-MNPs are incorporated into the lysosome of SMC. The MNPs have no inflammation impact, but decrease the viability of SMC. The other questions about metabolism and other impacts will be the next subject of further studies.
Song Zhang and Xiangjian Chen contributed equally to this work.
The authors gratefully acknowledge the support of National Natural Science Foundation of China (No. 60571031, 60501009 90406023, 30570745, and 30772781), National Basic Research Program of China (No. 2006CB933206 and 2006CB705606), and the fund of Key Laboratory of Jiangsu Province (XK200705).
- Sjögren C, Johansson C, Naevestad A, Sontum P, Briley-Saebo K, Fahlvik A: Magn. Reson. Imaging. 1997, 15: 55. 10.1016/S0730-725X(96)00335-9View ArticleGoogle Scholar
- Roger J, Pons JN, Massart R, Halbreich A, Bacri JC: Eur. Phys. J. Appl. Phys.. 1999, 5: 321. COI number [1:CAS:528:DyaK1MXjvFajsL4%3D]; Bibcode number [1999EPJAP...5..321R] 10.1051/epjap:1999144View ArticleGoogle Scholar
- Perez JM, O’Loughin T, Simeone FJ, Weissleder R, Josephson L: J. Am. Chem. Soc. 2002, 124: 2856. COI number [1:CAS:528:DC%2BD38XhsFWrtrs%3D] 10.1021/ja017773nView ArticleGoogle Scholar
- Dyal A, Loos K, Noto M, Chang SW, Spagnoli C, Shafi KVPM, et al.: J. Am. Chem. Soc. 2003, 125: 1684. COI number [1:CAS:528:DC%2BD3sXmslaktQ%3D%3D] 10.1021/ja021223nView ArticleGoogle Scholar
- Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al.: Nano Lett.. 2005, 5: 1003. COI number [1:CAS:528:DC%2BD2MXjslers7o%3D]; Bibcode number [2005NanoL...5.1003V] 10.1021/nl0502569View ArticleGoogle Scholar
- Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, et al.: J. Am. Chem. Soc. 2005, 127: 5732. COI number [1:CAS:528:DC%2BD2MXivVert7o%3D] 10.1021/ja0422155View ArticleGoogle Scholar
- Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C: Cancer Res.. 2000, 60: 8.Google Scholar
- Song M, Zhang RY, Dai YY, Gao F, Chi HM, Lv G, et al.: Biomaterials. 2006, 27: 4230. COI number [1:CAS:528:DC%2BD28XktVWrtbY%3D] 10.1016/j.biomaterials.2006.03.021View ArticleGoogle Scholar
- Zhang RY, Wang XM, Wu CH, Song M, Li JY, Lv G, et al.: Nanotechnology. 2006, 17: 3622. COI number [1:CAS:528:DC%2BD28XhtVaksLvP]; Bibcode number [2006Nanot..17.3622Z] 10.1088/0957-4484/17/14/043View ArticleGoogle Scholar
- Dobson J: Drug Dev. Res.. 2006, 67: 55. COI number [1:CAS:528:DC%2BD28XltF2msb4%3D] 10.1002/ddr.20067View ArticleGoogle Scholar
- Dandamudi S, Campbell RB: Biomaterials. 2007, 28: 4673. COI number [1:CAS:528:DC%2BD2sXptFygu7o%3D] 10.1016/j.biomaterials.2007.07.024View ArticleGoogle Scholar
- Ito A, Shinkai M, Honda H, Kobayashi T: Cancer Gene Ther.. 2001, 8: 649. COI number [1:CAS:528:DC%2BD3MXnt1eks7w%3D] 10.1038/sj.cgt.7700357View ArticleGoogle Scholar
- Kawashita M, Tanaka M, Kokubo T, Inoue Y, Yao T, Hamada S, et al.: Biomaterials. 2005, 26: 2231. COI number [1:CAS:528:DC%2BD2cXhtVCiu73K] 10.1016/j.biomaterials.2004.07.014View ArticleGoogle Scholar
- Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat AI: Environ. Health Perspect.. 2007, 115: 403. COI number [1:CAS:528:DC%2BD2sXjvFWnuro%3D] 10.1289/ehp.8497View ArticleGoogle Scholar
- Muller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, et al.: Biomaterials. 2007, 28: 1629. COI number [1:CAS:528:DC%2BD2sXktlOnug%3D%3D] 10.1016/j.biomaterials.2006.12.003View ArticleGoogle Scholar
- Auffan M, Decome L, Rose J, Orsiere T, De Meo M, Briois V, et al.: Environ. Sci. Technol.. 2006, 40: 4367. COI number [1:CAS:528:DC%2BD28Xkslymtrs%3D] 10.1021/es060691kView ArticleGoogle Scholar
- Sahoo SK, Labhasetwar V: Drug Discov. Today. 2003, 8: 1112. COI number [1:CAS:528:DC%2BD3sXpvVWkurw%3D] 10.1016/S1359-6446(03)02903-9View ArticleGoogle Scholar
- Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, et al.: Biochimie. 1998, 80: 379. COI number [1:CAS:528:DyaK1cXmt1Sntbw%3D] 10.1016/S0300-9084(00)80006-1View ArticleGoogle Scholar
- Gupta AK, Gupta M: Biomaterials. 2005, 26: 3995. COI number [1:CAS:528:DC%2BD2MXisFWr] 10.1016/j.biomaterials.2004.10.012View ArticleGoogle Scholar
- Gupta AK, Gupta M: Biomaterials. 2005, 26: 1565. COI number [1:CAS:528:DC%2BD2cXptV2ltL0%3D] 10.1016/j.biomaterials.2004.05.022View ArticleGoogle Scholar
- Pisanic TR, Blackwell JD, Shubayev VI, Finones RR, Jin S: Biomaterials. 2007, 28: 2572. COI number [1:CAS:528:DC%2BD2sXis1CrsLk%3D] 10.1016/j.biomaterials.2007.01.043View ArticleGoogle Scholar
- R.S. Molday, US Patent 4452773 (1984)Google Scholar
- Fauconnier N, Pons JN, Roger J, Bee A: J. Colloid Interf. Sci.. 1997, 194: 427. COI number [1:CAS:528:DyaK2sXnsVOmtbw%3D] 10.1006/jcis.1997.5125View ArticleGoogle Scholar
- Fauconnier N, Bee A, Roger J, Pons JN: J. Mol. Liq.. 1999, 83: 233. 10.1016/S0167-7322(99)00088-4View ArticleGoogle Scholar
- Ma M, Zhang Y, Yu W, Shen HY, Zhang HQ, Gu N: Colloid Surf. A. 2003, 212: 219. COI number [1:CAS:528:DC%2BD38XptFegs74%3D] 10.1016/S0927-7757(02)00305-9View ArticleGoogle Scholar
- Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H: Biomaterials. 2005, 26: 2685. COI number [1:CAS:528:DC%2BD2cXhtVChsrrE] 10.1016/j.biomaterials.2004.07.023View ArticleGoogle Scholar
- Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, et al.: Bioconjug. Chem.. 2005, 16: 1181. COI number [1:CAS:528:DC%2BD2MXpsleqsrs%3D] 10.1021/bc050050zView ArticleGoogle Scholar
- Fang H, Ma CY, Wan TL, Zhang M, Shi WH: J. Phys. Chem. C. 2007, 111: 1065. COI number [1:CAS:528:DC%2BD28XhtlKjs7zN] 10.1021/jp0672048View ArticleGoogle Scholar
- Zhou JK, Leuschner C, Kumar C, Hormes JF, Soboyejo WO: Biomaterials. 2006, 27: 2001. COI number [1:CAS:528:DC%2BD2MXht12isLfM] 10.1016/j.biomaterials.2005.10.013View ArticleGoogle Scholar
- Selim KMK, Ha YS, Kim SJ, Chang Y, Kim TJ, Lee GH, et al.: Biomaterials. 2007, 28: 710. COI number [1:CAS:528:DC%2BD28XhtFKhsbnM] 10.1016/j.biomaterials.2006.09.014View ArticleGoogle Scholar
- Sou K, Goins B, Takeoka S, Tsuchida E, Phillips WT: Biomaterials. 2007, 28: 2655. COI number [1:CAS:528:DC%2BD2sXis1Crsbk%3D] 10.1016/j.biomaterials.2007.01.041View ArticleGoogle Scholar
- Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, et al.: Biomaterials. 2007, 28: 2959. COI number [1:CAS:528:DC%2BD2sXktFOktL4%3D] 10.1016/j.biomaterials.2007.03.006View ArticleGoogle Scholar
- Reid MB, Li YP: Respir. Res.. 2001, 2: 269. COI number [1:CAS:528:DC%2BD3MXosVequ78%3D] 10.1186/rr67View ArticleGoogle Scholar
- Gupta AK, Berry C, Gupta M, Curtis A: IEEE Trans. Nanobiosci.. 2003, 2: 255. 10.1109/TNB.2003.820279View ArticleGoogle Scholar
- Mosmann T: J. Immunol. Methods. 1993, 95: 9.Google Scholar